ILUVIEN® Widely Available To DME Patients in the U.S.

On-demand Launch Event Features the first U.S. Patient Injections of ILUVIEN

ATLANTA, April 21, 2015 /PRNewswire/ — Alimera Sciences, Inc. ALIM, +1.01%(Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Experience the interactive Multimedia News Release here
The live web event was supported by eight leading retina specialists and one glaucoma specialist who shared early clinical experiences with ILUVIEN, showed videos of first patient injections, discussed patient case studies, presented clinical information and fielded questions from their colleagues around the country. The webcast is now available for on-demand viewing on Alimera’s product website,
“Kicking off the ILUVIEN U.S. commercial launch through a live webcast was an excellent way to quickly and effectively communicate the clinical attributes of ILUVIEN. The excitement and enthusiasm we felt from the physicians, both in the room and online, was quite evident,” said Dan Myers, president and chief executive officer of Alimera. “For those physicians unable to attend the live event, we are pleased to offer them the same opportunity to learn from their peers through the on-demand webinar link on the ILUVIEN website.”
“The level of engagement we felt from our colleagues, both during and after the webcast, is a testament to their eagerness to provide their patients with a multiyear implant that is effective as well as convenient,” said Nancy Holekamp, M.D., retina specialist at Pepose Vision, Chesterfield, Missouri, and moderator of the webcast event. “It is not surprising that the product has been so well embraced by both the physician and patient communities. The feedback from patients involved in the initial round of injections has been extremely encouraging.”……..
Read more:
Source: Market Watch